How Alcohol Disrupts Gut-Liver Communication and Fuels Liver Disease

Alcohol-associated liver disease (ALD) is one of the leading causes of liver transplantation and mortality worldwide. With limited treatment options available, researchers are working to uncover the biological mechanisms that drive disease progression in order to find new therapeutic avenues.

A team at the University of California San Diego School of Medicine has found that chronic alcohol use disrupts a gut–liver signaling pathway crucial for maintaining bacterial balance. Their findings, published in Nature, show that prolonged alcohol exposure reduces the expression of muscarinic acetylcholine receptor M4 (mAChR4), a protein that mediates key communication signals in the gut.

When mAChR4 levels fall, the formation of goblet cell-associated antigen passages (GAPs) is impaired. These structures normally play an important role in teaching the immune system to mount protective antimicrobial responses, limiting the movement of harmful bacteria beyond the gut barrier. Without sufficient GAP activity, bacteria can more easily translocate to the liver, worsening injury from alcohol exposure and increasing the severity of ALD.

The researchers studied both human liver biopsies and mouse models of ALD to support these observations. They found that restoring mAChR4 function—either by chemically activating the receptor itself or by manipulating related signaling pathways—promoted the formation of GAPs and enhanced protection against disease progression.

Although the primary focus of the study was the gut–liver connection, the implications extend further. mAChR4 is also important in brain regions involved in reinforcing habits, supporting learning, and regulating addictive behaviors. Notably, reduced levels of mAChR4 have been observed in the brains of individuals with alcohol use disorder (AUD). These connections raise the possibility that therapies aimed at activating mAChR4 could provide benefits for both ALD and AUD.

The path toward treatment may already be partially established. Drugs that target mAChR4 are currently under clinical evaluation for schizophrenia. According to the study, such compounds could feasibly be repurposed to address alcohol-related liver and brain conditions. However, further work is needed to test efficacy and safety for these new indications.